Retreating Arrowhead axes CSO in RNAi rout; Impel raises $36M for platform tech
Now that Arrowhead $ARWR has decided to chop out everything it has in the clinic, along with about a third of its staff, the biotech is giving its CSO the boot as well. In an 8-K filed with the SEC, Arrowhead said it had notified David Lewis that his job terminates on December 13. The retreat at Arrowhead has helped cast a pall over the RNAi field. A few weeks ago the biotech was forced to put its lead program on hold, and then followed up this week with the news that it is abandoning three clinical-stage programs. The news triggered a meltdown in its share price.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.